Already the largest patent infringement verdict in U.S. history, the $2.5 billion in damages awarded to Merck’s Idenix unit could swell to as much as three times the amount assessed by a federal jury in Wilmington on Thursday.
After a nearly two-week trial, the jury upheld the validity of a patent Merck acquired on hepatitis C treatments back in 2014, and said California-based Gilead Sciences Inc. owed 10 percent royalties on the $25.4 billion it had made on sales of its Sovaldi and Harvoni drugs through August.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
